Please assess the completion status of the following clinical trial:

Trial Title: Chantix in Adult Smokers With Attention Deficit Hyperactivity Disorder (ADHD)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female outpatients from 18-60 years of age;~* A cigarette smoking history of at least 3 months, and currently smoking;~* An interest in quitting smoking and a willingness to comply with all study procedures and medication instructions;~* A current DSM-IV-TR diagnosis of ADHD confirmed by clinical psychiatric evaluation and/or ADHD module of structured diagnostic interview, completed by study clinician.~* For females of child-bearing potential: pregnancy test at screening visit is negative and the subject does not plan to become pregnant during the study.~Exclusion Criteria:~* Pregnancy or breast-feeding;~* Clinically significant and/or unstable medical condition including renal, hepatic, or neurological, based upon a medical history and vital signs;~* Ongoing treatment with medications which may be affected (altered blood levels) if subjects stop smoking in the study, including insulin, theophylline, and blood thinners, as determined by clinician;~* Clinically significant cardiovascular history, including myocardial infarction, untreated hypertension, atrial fibrillation, or arrhythmia;~* Current untreated psychiatric comorbidity which the investigator judges to be of greater than mild severity, including Major Depressive Disorder;~* Current psychiatric comorbidity, including suicidality, homicidality, psychosis, determined by the clinician to be clinically significant and/or unstable~* Lifetime history of DSM-IV Bipolar I disorder, Schizophrenia, or suicide attempt as determined through clinical evaluation or diagnostic interview;~* Currently (within 3 months) meets DSM-IV criteria for abuse or dependence for any psychoactive substance other than nicotine;~* Current treatment with mood stabilizers, anti-psychotics, nicotine replacement therapies, or varenicline;~* Mental retardation (IQ \< 75);~* History of intolerance or allergy to varenicline.~* Clinically significant abnormal screening values including:~  * Consistent readings of hypertension (\>140/90) during screening period (including screening and baseline visits), defined as two or more readings (each being the average of three measurements) at a single visit with systolic blood pressure, SBP \> 140 and/or diastolic blood pressure, DBP, \> 90, and confirmed by manual reading.~Subjects with isolated incidences (of triplicate average BP) of SBP \> 140 and/or DBP \> 90 at baseline/week 0 visit, confirmed by manual reading, which are determined to be clinically significant.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Adults who meet DSM-IV-TR criteria for ADHD and smoke cigarettes.

Based on this trial design, predict the completion outcome and termination type (if applicable).